To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts
of participants with relapsed or refractory monocytic AML and CMML in order to estimate the
maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended
Phase 2 dose (RP2D) and dose schedule as monotherapy.
This is a Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose Expansion Study to
Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity
Study of IO-202 as Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients
with Monocytic Differentiation and in Relapsed/Refractory Chronic Myelomonocytic Leukemia
1. Patients must be ≥18.
2. For the Part 1 Dose-Escalation Phase, patients must be diagnosed with the following:
1. Relapsed AML with myelomonocytic or monoblastic/monocytic differentiation
according to the World Health Organization (WHO) 2016 criteria and has failed
treatment with available therapies known to be active for AML.
2. CMML according to World Health Organization (WHO) 2016 criteria and has failed
treatment with available therapies known to be active for CMML.
3. Part 2 Expansion Phase:
a) AML with myelomonocytic or monoblastic/monocytic differentiation according to the
World Health Organization 2016 criteria and has failed treatment with available
therapies known to be active for AML.
4. Patients must be amenable to serial BM aspirates/biopsies and peripheral blood
sampling during the study.
5. Patients must be able to understand and willing to sign an informed consent. A legally
authorized representative may consent on behalf of a patient who is otherwise unable
to provide informed consent, if acceptable to and approved by the site and/or site's
Institutional Review Board (IRB) or Ethics Committee.
6. Patients must have an ECOG performance status of 0 to 2, inclusive.
7. Patients must have adequate hepatic function
8. Patients must have adequate renal function
9. Patients must be recovered from any clinically relevant toxic effects of any prior
surgery, radiotherapy, or other therapy intended for the treatment of cancer (patients
with residual Grade 1 toxicity, or any grade of alopecia, are allowed; patients with
peripheral neuropathy that is not more than Grade 2 and stable are allowed).
10. Patients must be off calcineurin inhibitors (e.g., cyclosporine, tacrolimus) for at
least 4 weeks prior to study drug treatment.
11. Female patients with reproductive potential must have a negative serum pregnancy test
within 7 days prior to the start of therapy.
1. Patients who have previously received IO-202.
2. Patients who have undergone HSCT within 60 days of the first dose of IO-202, or
patients on immunosuppressive therapy post human stem cell transplantation (HSCT) at
the time of screening, or with clinically significant graft-versus-host disease (GVHD)
(the use of a stable dose of oral steroids post-HSCT of <10 mg prednisone/day or dose
equivalent of other corticosteroid and/or topical steroids for ongoing skin GVHD is
permitted with Medical Monitor approval).
3. Patients who received systemic anti-cancer therapy or radiotherapy <7 days prior to
their first day of study drug administration (Hydroxyurea or leukapheresis is allowed
up to 24 hours prior to the first dose. However, hydroxyurea must be ceased 24 hours
prior to the first dose of IO-202 treatment in Cycle 1).
4. Patients who received an investigational agent <7 days prior to their first day of
study drug administration. In addition, the first dose of IO-202 should not occur
before a period ≥5 half-lives of the investigational agent has elapsed.
5. Patients for whom potentially curative anti-cancer therapy is available.
6. Patients who are pregnant or breast feeding.
7. Patients with uncontrolled, active infection.
8. Patients with known hypersensitivity to any of the components of the IO-202
9. History of another malignancy in the previous 5 years, unless cured by surgery alone
and continuously disease free. Exceptions include appropriately treated carcinoma in
situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, localized
prostate cancer that has been treated surgically with curative intent and presumed
cured, resected breast cancer that has been treated with or is currently being treated
with adjuvant hormonal and/or other endocrine therapy, resected prostate cancer that
has been treated with androgen deprivation therapy and prostate-specific antigen level
is stable or 0.
10. Patients with New York Heart Association (NYHA) Class III or IV congestive heart
failure (CHF) or left ventricular ejection fraction (LVEF) <40% by echocardiogram
(ECHO) or multi-gated acquisition (MUGA) scan ≤28 days prior to Cycle 1, Day 1.
11. Any of the following in the previous 6 months: myocardial infarction, congenital long
QT syndrome, Torsades de pointes, clinically significant arrhythmias (including
sustained ventricular tachyarrhythmia and ventricular fibrillation), and left anterior
hemiblock (bifascicular block), unstable angina, coronary/peripheral artery bypass
graft, symptomatic CHF (NYHA class III or IV), cerebrovascular accident, transient
ischemic attack, or pulmonary embolism. Patients with asymptomatic right bundle branch
block are allowed.
12. Ongoing cardiac dysrhythmias of NCI CTCAE, Version 5.0, Grade ≥2 or QT interval
corrected by Fridericia's formula (QTcF) interval >470 msec at screening.
13. Known or suspected hypersensitivity to recombinant human proteins.
14. Active bacterial, viral, and/or fungal infection including hepatitis B (HB), hepatitis
C, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome
(AIDS)-related illness, or active Covid-19 infection.
15. Patients with any psychological, familial, sociological, or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule; those
conditions should be discussed with the patient before trial entry.
16. Patients with clinical signs and/or symptoms suggesting active, uncontrolled central
nervous system (CNS) leukemia or known active, uncontrolled CNS leukemia (a lumbar
puncture is not required in patients without signs or symptoms that are suggestive of
CNS leukemia). Note: Patients with controlled CNS leukemia (documented by 2
consecutive assessments of zero blast count in cerebrospinal fluid), and who are still
receiving intrathecal (IT) therapy at study entry are considered eligible and will
continue to receive IT therapy.
17. Patients with immediately life-threatening, severe complications of leukemia such as
uncontrolled bleeding, pneumonia with hypoxia or shock, or disseminated intravascular
18. Patients known to be refractory to platelet or packed red cell transfusions per
19. Donor Lymphocyte Infusion within 30 days prior to first IO-202 administration.
20. Current active treatment in another interventional therapeutic clinical study.
21. Chronic systemic corticosteroid treatment with a dose of ≥10 mg prednisone/day or dose
equivalent of another corticosteroid. Topical applications, inhaled sprays, eye drops,
local injections of corticosteroids, and systemic steroids required for acute medical
interventions are allowed.
22. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the Investigator, would make the patient
inappropriate for entry into this study.
23. Acute Promyelocytic Leukemia patients or patients with known Philadelphia chromosome
(Ph+) positive AML or chronic myelogenous leukemia (CML) blast crisis.
24. Hyperleukocytosis (leukocytes ≥25 x 10e9/L) at first dose of IO-202. These patients
may be treated with hydroxyurea or receive leukapheresis treatment according to
routine practice, and enrolled in the study when the leukocyte count falls below 25 x
25. Patients who are investigational site staff members or relatives of those site staff
members or patients who are Immune-Onc employees directly involved in the conduct of